Guaiacol

Guaiacol

SCHEMBL4090352

CCCCCC(=O)O.COc1ccccc1O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
TP53 P04637 1/20 0.56
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C8 P10632 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
CYP2C19 P33261 1/20 0.50
AKR1B1 P15121 1/20 0.50
GPR84 Q9NQS5 6/20 0.48
PPARG P37231 6/20 0.48
PPARD Q03181 6/20 0.48
PPARA Q07869 6/20 0.48
HDAC11 Q96DB2 5/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Heptanoate SCHEMBL4083652 0.98 TSHR (0.55) TSHRCA1CA2TP53CYP1A2
Octanoic Acid SCHEMBL4095208 0.98 TSHR (0.55) TSHRCA1CA2TP53CYP1A2
Nonanoate SCHEMBL4090842 0.98 TSHR (0.55) TSHRCA1CA2TP53CYP1A2
Guaiacol SCHEMBL4085621 0.95 TSHR (0.58) TSHRCA1CA2TP53LMNA
Guaiacol SCHEMBL1824093 0.89 TSHR (0.62) TSHRCA1CA2TP53LMNA
Guaiacol SCHEMBL3361883 0.87 CA1 (0.69) TSHRCA1CA2TP53LMNA
3-Octanone SCHEMBL28007280 0.86 CYP1A2 (0.56) TSHRCA1CA2TP53CYP1A2
Tetradecane SCHEMBL15009441 0.85 TP53 (0.72) TSHRCA1CA2TP53LMNA
Guaiacol SCHEMBL4089861 0.83 CA1 (0.69) TSHRCA1CA2TP53LMNA
Octanoic Acid SCHEMBL9716530 0.83 GPR84 (0.65) TSHRLMNACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2237683-B1 METHOD OF FLAVORING GIVAUDAN SA (CH) 2015-11-11 EP disclosed
US-20130177688-A1 Method of Flavoring GIVAUDAN S.A. (CH) 2013-07-11 US disclosed
US-20090186138-A1 Method of Flavoring GIVAUDAN SA (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186138-A1 Method of Flavoring TAS2R5, TAS2R50, TAS2R10 TSHR 4345/4885CA1 1848/4885CA2 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.